USRE33653E - Human recombinant interleukin-2 muteins - Google Patents
Human recombinant interleukin-2 muteins Download PDFInfo
- Publication number
- USRE33653E USRE33653E US07/386,207 US38620789A USRE33653E US RE33653 E USRE33653 E US RE33653E US 38620789 A US38620789 A US 38620789A US RE33653 E USRE33653 E US RE33653E
- Authority
- US
- United States
- Prior art keywords
- mutein
- interleukin
- ifn
- dna
- native
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
TABLE I ______________________________________ EXTRACT ANTIVIRAL ACTIVITY (U/ml) ______________________________________ pSY2501 6 × 10.sup.5pβ1trp 1 × 10.sup.5 ptrp3 (control) 30 ______________________________________
______________________________________ Ingredient Concentration ______________________________________ NH.sub.4Cl 20 mM K.sub.2 SO.sub.4 16.1 mM KH.sub.2 PO.sub.4 7.8 mM Na.sub.2 HPO.sub.4 12.2 mM MgSO.sub.4.7H.sub.2O 3 mM Na.sub.3 citrate.2H.sub.2 O 1.5 mM MnSO.sub.4.4H.sub.2O 30 μM ZnSO.sub.4.7H.sub.2O 30 μM CuSO.sub.4.5H.sub.2O 3 μM L-tryptophan 70 mg/l FeSO.sub.4.7H.sub.2 O 72 μM thiamine.HCl 20 mg/l glucose 40 g/l ______________________________________ pH cotrol with NH.sub.4 OH
______________________________________ Approximate Initial Ingredient Concentration ______________________________________ Na.sub.3 Citrate.2H.sub.2O 3 mM KH.sub.2 PO.sub.4 30 mM (NH.sub.4).sub.2 SO.sub.4 74 mM MgSO.sub.4.7H.sub.2 O 46 μM ZnSO.sub.4.7H.sub.2 O 46 μM CuSO.sub.4.5H.sub.2 O 1-2 μM L-tryptophan 350 μM FeSO.sub.4.7H.sub.2 O 74 μM thiamine.HCl 0.002% glucose 0.5% ______________________________________
TABLE I __________________________________________________________________________ NK Cell Cytotoxicity by Interferon (specific % .sup.51 Cr release ± SEM) IFN (units/ml) Target Effector Cell Cells 0 10 30 100 300 1000 __________________________________________________________________________ T24 PMC 7.23 ± 5.1 23.1 ± 4.4 24.4 ± 1.1 34.1 ± 2.5 50.0 ± 2.0 40.4 ± 4.4 Chang PMC 4.7 ± 0.5 7.2 ± 0.8 9.5 ± 1.7 15.9 ± 1.3 21.9 ± 1.4 26.9 ± 1.8 Chang NK Enr 19.2 ± 4.6 39.4 ± 4.1 ND 54.2 ± 6.1 ND 41.7 ± 5.5 K562 NK Enr 41.0 ± 4.6 48.4 ± 3.6 ND 62.2 ± 3.5 ND 63.2 ± 3.5 __________________________________________________________________________
TABLE II ______________________________________ Clones IL-2 Activity (μ/ml) ______________________________________ pIL2-7 (negative control) 1 pLW21 (positive control) 113,000 pLW42 660 pLW44 1,990 pLW46 123,000 ______________________________________
______________________________________ (NH.sub.4).sub.2 SO.sub.4 150 mM KH.sub.2 PO.sub.4 21.6 mM Na.sub.3 Citrate 1.5 mM ZnSO.sub.4.7H.sub.2O 30 μM MnSO.sub.4.H.sub.2O 30 μM CuSO.sub.4.5H.sub.2O 1 μM ______________________________________ pH adjusted to 6.50 with 2.5 N NaOH autoclaved
______________________________________ Sterile Additions (post autoclave) ______________________________________ MgSO.sub.4.7H.sub.2O 3 mM FeSO.sub.4 100 μM L-tryptophan 14 mg/l Thiamine.HCl 20 mg/l Glucose 5 g/l Tetracycline 5 mg/l Ethanol 2% Casamino acids 2% ______________________________________
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/386,207 USRE33653E (en) | 1983-04-15 | 1989-07-26 | Human recombinant interleukin-2 muteins |
BG96074A BG60506B2 (en) | 1989-07-26 | 1992-03-16 | Human recombinant interleukin-2-mutien |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48616283A | 1983-04-15 | 1983-04-15 | |
US07/386,207 USRE33653E (en) | 1983-04-15 | 1989-07-26 | Human recombinant interleukin-2 muteins |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US48616283A Continuation-In-Part | 1982-10-19 | 1983-04-15 | |
US06/564,224 Reissue US4518584A (en) | 1983-04-15 | 1983-12-20 | Human recombinant interleukin-2 muteins |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE33653E true USRE33653E (en) | 1991-07-30 |
Family
ID=23930849
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/564,224 Ceased US4518584A (en) | 1983-04-15 | 1983-12-20 | Human recombinant interleukin-2 muteins |
US07/386,207 Expired - Lifetime USRE33653E (en) | 1983-04-15 | 1989-07-26 | Human recombinant interleukin-2 muteins |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/564,224 Ceased US4518584A (en) | 1983-04-15 | 1983-12-20 | Human recombinant interleukin-2 muteins |
Country Status (1)
Country | Link |
---|---|
US (2) | US4518584A (en) |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
US5965726A (en) | 1992-03-27 | 1999-10-12 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/ instability regions of mRNA |
US6008319A (en) | 1996-12-23 | 1999-12-28 | University Of Southern California | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof |
US20030036170A1 (en) * | 1992-01-31 | 2003-02-20 | Aventis Behring L.L.C. | Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
US20030124678A1 (en) * | 2001-08-13 | 2003-07-03 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
US6602705B1 (en) | 1998-12-31 | 2003-08-05 | Chiron Corporation | Expression of HIV polypeptides and production of virus-like particles |
US20030198621A1 (en) * | 2001-07-05 | 2003-10-23 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
US20030223961A1 (en) * | 2000-07-05 | 2003-12-04 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US6689783B2 (en) | 2001-03-29 | 2004-02-10 | Schering Corporation | Aryl oxime-piperazines useful as CCR5 antagonists |
US6689879B2 (en) | 1998-12-31 | 2004-02-10 | Chiron Corporation | Modified HIV Env polypeptides |
US6696063B1 (en) | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
WO2004085406A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
US20050164185A1 (en) * | 2001-12-31 | 2005-07-28 | Gideon Schreiber | Ifnar2 mutants, their production and use |
US20050214256A1 (en) * | 2001-08-31 | 2005-09-29 | Chiron Corporation | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US20060029572A1 (en) * | 2002-06-03 | 2006-02-09 | Applied Research Systems Ars Holding N.V. | Treatment of hepatitis c in the asian population with subcutaneous interferonbeta |
US20060057115A1 (en) * | 1998-12-31 | 2006-03-16 | Zur Megede Jan | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US20070020622A1 (en) * | 2001-09-14 | 2007-01-25 | Invitrogen Corporation | DNA Polymerases and mutants thereof |
WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US20080025957A1 (en) * | 2003-11-13 | 2008-01-31 | Yeda Research And Development Co. Ltd. P. O. Box 95 | Stem Cells Suitable for Transplantation, their Preparation and Pharmaceutical Compositions Comprising Them |
WO2008019968A1 (en) | 2006-08-16 | 2008-02-21 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
WO2008071587A2 (en) | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors |
WO2008145562A1 (en) | 2007-05-30 | 2008-12-04 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
US20090047339A1 (en) * | 1998-12-31 | 2009-02-19 | Barnett Susan W | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
EP2042196A2 (en) | 2001-10-10 | 2009-04-01 | Neose Technologies, Inc. | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
EP2042509A1 (en) | 1995-07-16 | 2009-04-01 | Yeda Research And Development Company, Ltd. | Modulators of the function of FAS receptors and other proteins |
EP2045265A1 (en) | 2005-09-22 | 2009-04-08 | Biocompatibles Uk Ltd. | GLP-1 fusion peptides, their production and use |
EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
WO2009080534A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
WO2009098700A1 (en) | 2008-02-10 | 2009-08-13 | Yeda Research And Development Co. Ltd | Siva 3, its preparation and use |
EP2298354A2 (en) | 2001-10-10 | 2011-03-23 | BioGeneriX AG | Remodelling and glycoconjugation of interferon-beta |
US8388954B2 (en) | 2003-04-09 | 2013-03-05 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Stabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form |
US9732134B2 (en) | 2009-01-21 | 2017-08-15 | Amgen Inc. | Method of treating graft versus host disease using IL-2 muteins |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
US10851144B2 (en) | 2015-04-10 | 2020-12-01 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10961310B2 (en) | 2017-03-15 | 2021-03-30 | Pandion Operations, Inc. | Targeted immunotolerance |
US11491205B2 (en) | 2020-01-14 | 2022-11-08 | Synthekine, Inc. | Biased IL2 muteins methods and compositions |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
Families Citing this family (323)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925919A (en) * | 1984-04-25 | 1990-05-15 | Roland Mertelsmann | Purified interleukin 2 |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4921699A (en) * | 1983-06-01 | 1990-05-01 | Hoffman-La Roche Inc. | Polypeptides having interferon activity |
US4816566A (en) * | 1983-06-01 | 1989-03-28 | Hoffmann-La Roche, Inc. | Polypeptides having interferon activity |
JPS60115528A (en) * | 1983-11-28 | 1985-06-22 | Takeda Chem Ind Ltd | Human interleukin-2 protein, its production and pharmacological composition containing the same |
JPS60118196A (en) * | 1983-11-30 | 1985-06-25 | Takeda Chem Ind Ltd | Production of interferon |
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
US4711845A (en) * | 1984-08-31 | 1987-12-08 | Cetus Corporation | Portable temperature-sensitive control cassette |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
US4636463A (en) * | 1984-04-05 | 1987-01-13 | Scripps Clinic And Research Foundation | Antibodies to human interleukin-2 induced by synthetic polypeptides |
EP0158487B1 (en) * | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
US4908434A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Process for preparing purified interleukin-2 |
EP0569687B1 (en) * | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
US4666848A (en) * | 1984-08-31 | 1987-05-19 | Cetus Corporation | Polypeptide expression using a portable temperature sensitive control cassette with a positive retroregulatory element |
DE3581730D1 (en) | 1984-10-15 | 1991-03-14 | Cetus Corp | HUMAN TUMORNCROSIS FACTOR. |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5342614A (en) * | 1984-12-21 | 1994-08-30 | Otsuka Pharmaceutical Co., Ltd. | Method of treating arthritus or inflammation with IL-1β or derivatives thereof |
US6107465A (en) * | 1984-12-21 | 2000-08-22 | Otsuka Pharmaceutical Co., Ltd. | IL-1β and derivatives thereof and drugs |
US4752585A (en) * | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
CA1340265C (en) | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
US5422105A (en) * | 1985-02-05 | 1995-06-06 | Cetus Oncology Corporation | Use of recombinant colony stimulating factor 1 |
US4847201A (en) * | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
US5556620A (en) * | 1985-02-05 | 1996-09-17 | Cetus Oncology Corporation | Use of recombinant colony stimulating factor-1 to enhance wound healing |
US5104650A (en) * | 1985-02-05 | 1992-04-14 | Cetus Corporation | Uses of recombinant colony stimulating factor-1 |
DE3683186D1 (en) * | 1985-04-25 | 1992-02-13 | Hoffmann La Roche | RECOMBINANT HUMANINTERLEUKIN-1. |
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4818698A (en) * | 1985-08-23 | 1989-04-04 | Toyo Jozo Co., Ltd. | Polypeptides and preparation process thereof |
US5239065A (en) * | 1985-08-23 | 1993-08-24 | Asahi Kasei Kogyo Kabushiki Kaisha | DNA encoding human CV/2n superoxide dismutase muteins with at least serine or alanine at either or both residues 6 and 111 |
US5643565A (en) * | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
US5100664A (en) * | 1985-09-20 | 1992-03-31 | Cetus Corporation | Human IL-2 as a vaccine adjuvant |
US4818769A (en) * | 1985-09-20 | 1989-04-04 | Cetus Corporation | Method of controlling stress-related disease in livestock by administration of human IL-2 |
CA1297003C (en) * | 1985-09-20 | 1992-03-10 | Jack H. Nunberg | Composition and method for treating animals |
US5102872A (en) * | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
US5656266A (en) * | 1985-11-19 | 1997-08-12 | Schering Corporation | Method of using interleukin-4 |
US5017691A (en) * | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US5807996A (en) * | 1985-11-19 | 1998-09-15 | Schering Corporation | Fused polypeptides comprising interleukin-4 polypeptide fragments |
DK585886A (en) * | 1985-12-24 | 1987-06-25 | Takeda Chemical Industries Ltd | IMMUNSTIMENTAL AGENTS AND USE THEREOF |
US4933433A (en) * | 1986-01-31 | 1990-06-12 | E. I. Du Pont De Nemours And Company | Recombinant interleukin-2 composition and process for making it |
US5425940A (en) * | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US4863727A (en) * | 1986-04-09 | 1989-09-05 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US4879111A (en) * | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
US5451521A (en) * | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
US5900476A (en) * | 1986-05-30 | 1999-05-04 | The Scripps Research Institute | Therapeutic domains of van Willebrand factor |
US4832686A (en) * | 1986-06-24 | 1989-05-23 | Anderson Mark E | Method for administering interleukin-2 |
US4745180A (en) * | 1986-06-27 | 1988-05-17 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using heparin fragments |
GR871029B (en) | 1986-07-14 | 1987-11-02 | Genetics Inst | Novel osteoinductive factors |
WO1988000970A2 (en) * | 1986-08-08 | 1988-02-11 | Regents Of The University Of Minnesota | Method of culturing leukocytes |
US4777242A (en) * | 1986-10-10 | 1988-10-11 | Phillips Petroleum Company | Purification of recombinant tumor necrosis factor |
EP0335900A4 (en) * | 1986-12-19 | 1990-12-27 | Immunex Corporation | Human interleukin-4 muteins |
WO1988005786A1 (en) * | 1987-02-06 | 1988-08-11 | Genetics Institute, Inc. | Colony stimulating factors having reduced levels of carbohydrate |
WO1988007084A1 (en) * | 1987-03-12 | 1988-09-22 | Amgen Inc. | Bovine growth hormone analogs |
US4938956A (en) * | 1987-04-01 | 1990-07-03 | International Minerals & Chemical Corp. | Synergistic immunostimulating composition and method |
CA1339757C (en) * | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Production of purified biologically active, bacterially produced recombinant human csf-1 |
US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
US4894333A (en) * | 1987-05-28 | 1990-01-16 | Immunex Corporation | Bovine interleukin-1α |
US5266311A (en) * | 1987-05-28 | 1993-11-30 | Immunex Corporation | Bovine interleukin-1α |
US5443964A (en) * | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
US5578468A (en) * | 1987-08-10 | 1996-11-26 | Duke University | Site-specific RNA cleavage |
US5162226A (en) | 1987-08-24 | 1992-11-10 | University Of Tennessee Research Corp. (U.T.R.C.) | Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products |
US5312911A (en) * | 1987-10-22 | 1994-05-17 | Merck & Co., Inc. | Cysteine-modified acidic fibroblast growth factor |
ZA887773B (en) | 1987-10-26 | 1989-07-26 | Immunex Corp | Interleukin-7 |
US5328988A (en) * | 1987-10-26 | 1994-07-12 | Immunex Corporation | Interleukin-7 |
US5714585A (en) * | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
US5066489A (en) * | 1988-03-28 | 1991-11-19 | Cetus Corporation | Combination therapy of IL-2 and DTIC for the treatment of melanoma |
US4999339A (en) * | 1988-03-28 | 1991-03-12 | Cetus Corporation | Combination therapy of IL-2 and DTIC for the treatment of melanoma |
FR2635527B1 (en) * | 1988-07-28 | 1992-06-12 | Roussel Uclaf | NON-GLYCOSYLATED RECOMBINANT HUMAN IL2 IN REDUCED FORM, PROCESS FOR OBTAINING IT, AND APPLICATION THEREOF AS A MEDICAMENT |
US5763573A (en) * | 1988-08-10 | 1998-06-09 | Chiron Corporation | GTPase activating protein fragments |
US5760203A (en) * | 1988-08-10 | 1998-06-02 | Chiron Corporation | Gap gene sequences |
ATE147633T1 (en) * | 1988-10-27 | 1997-02-15 | Univ Minnesota | IMMUNE AID FROM LIPOSOMES CONTAINING LYMPHOKINE IL -2 |
US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
US5621078A (en) * | 1989-03-22 | 1997-04-15 | Merck & Co., Inc. | Modified pseudomonas exotoxin PE40 |
WO1990012877A1 (en) * | 1989-04-19 | 1990-11-01 | Cetus Corporation | Multifunctional m-csf proteins and genes encoding therefor |
US5100378A (en) * | 1989-06-09 | 1992-03-31 | Neorx Corporation | Enhancement of target cell localization of lymphoid cells |
US6207798B1 (en) * | 1989-08-03 | 2001-03-27 | Merck & Co., Inc. | Modified PE40 toxin fusion proteins |
DE69033911D1 (en) * | 1989-10-24 | 2002-03-14 | Chiron Corp | SYSTEM FOR RELEASING INFECTIOUS PROTEINS |
CA2042093C (en) * | 1990-05-09 | 2002-12-24 | Gyula Hadlaczky | Cell line carrying an excess of mammalian centromeres |
IL98528A0 (en) * | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
US5849694A (en) * | 1990-07-16 | 1998-12-15 | Synenki; Richard M. | Stable and bioactive modified porcine somatotropin and pharmaceutical compositions thereof |
US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
US5310883A (en) * | 1990-11-23 | 1994-05-10 | American Cyanamid Company | Chimeric fibroblast growth factors |
US5250296A (en) * | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
EP0561960A1 (en) * | 1990-12-13 | 1993-09-29 | Immunex Corporation | Leukemia inhibitory factor receptors |
JP3303211B2 (en) * | 1991-04-26 | 2002-07-15 | 武田薬品工業株式会社 | bFGF mutein and method for producing the same |
IE922233A1 (en) * | 1991-07-10 | 1993-01-13 | Augusto C Ochoa | Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity |
WO1993012813A1 (en) * | 1991-12-31 | 1993-07-08 | Zymogenetics, Inc. | Methods and compositions for reducing blood loss |
US5602301A (en) | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
US5968477A (en) * | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
US20030220233A1 (en) * | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
US5582821A (en) * | 1994-07-22 | 1996-12-10 | Genetics Institute, Inc. | Methods for treating bleeding disorders |
US5632983A (en) | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
US5814485A (en) * | 1995-06-06 | 1998-09-29 | Chiron Corporation | Production of interferon-β (IFN-β) in E. coli |
US5763223A (en) | 1995-06-29 | 1998-06-09 | Immunex Corporation | DNA encoding a cytokine that induces apoptosis |
US6184200B1 (en) | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
US5731284A (en) * | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
US5641749A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
US5641750A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
US5837681A (en) * | 1996-02-23 | 1998-11-17 | Amgen Inc. | Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5741778A (en) * | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
US20030033617A1 (en) * | 1996-04-10 | 2003-02-13 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US20020160970A1 (en) * | 1996-04-10 | 2002-10-31 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6077697A (en) | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US7138251B1 (en) * | 1996-04-22 | 2006-11-21 | Amgen Inc. | Polynucleotides encoding a neurotrophic factor receptor |
US6455277B1 (en) * | 1996-04-22 | 2002-09-24 | Amgen Inc. | Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides |
EP1649868A1 (en) | 1996-05-31 | 2006-04-26 | National University of Ireland, Maynooth | IL-12 as an adjuvant for Bordetella pertussis vaccines |
JP4024366B2 (en) * | 1996-11-29 | 2007-12-19 | 株式会社林原生物化学研究所 | Polypeptide |
EP2003203A1 (en) | 1996-12-23 | 2008-12-17 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily |
JP2001512306A (en) * | 1997-01-08 | 2001-08-21 | ライフ テクノロジーズ,インコーポレイテッド | Methods for producing proteins |
AU735459B2 (en) | 1997-01-30 | 2001-07-12 | University Of Virginia Patent Foundation | Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor |
US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
US6852508B1 (en) | 1997-02-28 | 2005-02-08 | Genetics Institute, Llc | Chemokine with amino-terminal modifications |
US6159688A (en) | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods of producing polynucleotide variants |
US6787319B2 (en) * | 1997-04-16 | 2004-09-07 | American Home Products Corp. | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
US7005295B1 (en) | 1997-04-16 | 2006-02-28 | Wyeth | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
CA2302837A1 (en) | 1997-09-08 | 1999-03-18 | The General Hospital Corporation | Imaging agents for early detection and monitoring of cardiovascular plaque |
WO1999023229A1 (en) | 1997-10-30 | 1999-05-14 | Cornell Research Foundation, Inc. | A method of inhibiting an immune response to a recombinant vector |
US6110718A (en) | 1998-03-20 | 2000-08-29 | Wayne State University | Mammalian putative phosphatidylinositol-4-phosphate-5-kinase |
US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
US6426191B1 (en) | 1998-04-03 | 2002-07-30 | Hyseq, Inc. | Assays involving an IL-1 receptor antagonist |
US6294655B1 (en) | 1998-04-03 | 2001-09-25 | Hyseq, Inc. | Anti-interleukin-1 receptor antagonist antibodies and uses thereof |
US6541623B1 (en) | 1998-04-03 | 2003-04-01 | Hyseq, Inc. | Interleukin—1 receptor antagonist and uses thereof |
US6893838B1 (en) | 1998-04-07 | 2005-05-17 | Genetics Institute Llc | DADD, death activator death domain protein |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
US6432679B1 (en) | 1998-06-12 | 2002-08-13 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220 |
US7439061B2 (en) * | 1998-07-21 | 2008-10-21 | The Regents Of The University Of Michigan | DNA encoding the novel mammalian protein, Ire1p |
DE69932247T2 (en) * | 1998-08-21 | 2007-05-31 | Immunex Corp., Thousand Oaks | HUMAN IL-1 EPSILON DNA AND POLYPEPTIDE |
US6537554B1 (en) | 1998-09-10 | 2003-03-25 | Curagen Corporation | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
EP1939297A1 (en) | 1998-09-24 | 2008-07-02 | Pharmacia & Upjohn Company LLC | Alzheimer's disease secretase |
CA2346008A1 (en) * | 1998-10-13 | 2000-04-20 | American Home Products Corporation | G-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same |
US6191256B1 (en) * | 1998-11-20 | 2001-02-20 | Bayer Corporation | Recombinant factor VIII binding peptides |
US6225113B1 (en) | 1998-12-04 | 2001-05-01 | Genvec, Inc. | Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus |
CN1210400C (en) | 1999-01-14 | 2005-07-13 | 博尔德生物技术公司 | Methods for making proteins containing free cysteine residues |
US6953777B2 (en) * | 1999-03-11 | 2005-10-11 | Genetics Indtitute LLC | Use of interleukin-11 to prevent immune-mediated cytotoxicity |
NZ515678A (en) | 1999-04-28 | 2004-01-30 | Genetics Inst | Human GIL-19/AE289 proteins and polynucleotides encoding same |
US6514729B1 (en) | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
DK2067788T3 (en) | 1999-05-18 | 2015-10-19 | Dyax Corp | Fab fragment libraries and methods for using them |
US6455290B1 (en) | 1999-07-09 | 2002-09-24 | Pharmacia Italia S.P.A. | Tankyrase homolog protein (THP), nucleic acids, and methods related to the same |
US20030082534A1 (en) * | 1999-11-16 | 2003-05-01 | Peter Lind | Novel G protein-coupled receptors |
CA2388865A1 (en) * | 1999-11-16 | 2001-05-25 | Pharmacia & Upjohn Company | Novel g protein-coupled receptors |
US20030003451A1 (en) * | 2000-02-23 | 2003-01-02 | Gabriel Vogeli | Novel G protein-coupled receptors |
EP1276849A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
EP1935431A3 (en) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
EP3190126A1 (en) | 2000-05-26 | 2017-07-12 | Immunex Corporation | Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof |
US7259244B2 (en) | 2000-06-16 | 2007-08-21 | Nerviano Medical Sciences S.R.L. | Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same |
US20040014082A1 (en) * | 2000-08-11 | 2004-01-22 | Invitrogen Corporation | Highly homogeneous molecular markers for electrophoresis |
US20030104573A1 (en) * | 2000-09-11 | 2003-06-05 | Shimkets Richard A. | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
EP1911837B1 (en) * | 2000-09-28 | 2011-05-25 | Bioriginal Food & Science Corp. | FAD5-2 fatty acid desaturase family member and uses thereof |
US20030215813A1 (en) * | 2000-12-14 | 2003-11-20 | Roberds Steven L. | Human ion channels |
AU2002241922B2 (en) | 2001-01-17 | 2007-10-25 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20050069976A1 (en) * | 2001-02-14 | 2005-03-31 | Peter Lind | Protein-coupled receptor |
WO2002068683A2 (en) * | 2001-02-27 | 2002-09-06 | Virco Bvba | Circular probe amplification (cpa) using energy-transfer primers |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
US7364890B2 (en) * | 2001-07-28 | 2008-04-29 | Midwest Research Institute | Thermal tolerant avicelase from Acidothermus cellulolyticus |
US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
CA2463935A1 (en) * | 2001-09-18 | 2003-03-27 | Chiron Corporation | Methods for treating multiple sclerosis |
CA2462790A1 (en) | 2001-10-04 | 2003-04-10 | Immunex Corporation | Ul16 binding protein 4 |
WO2003049693A2 (en) * | 2001-12-06 | 2003-06-19 | Wyeth | Method and composition for inducing weight loss |
US6911321B2 (en) * | 2001-12-19 | 2005-06-28 | Genentech, Inc. | Non-human primate Fc receptors and methods of use |
KR101271635B1 (en) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
US6982080B2 (en) * | 2002-03-15 | 2006-01-03 | Wyeth | Hydroxyethyl starch—containing polypeptide compositions |
AU2003253593A1 (en) * | 2002-04-05 | 2003-11-03 | Richard A. Fishel | Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
DK1499733T3 (en) * | 2002-04-22 | 2010-07-12 | Novozymes Inc | Methods for preparing variants of a DNA sequence in filamentous fungi |
WO2003095492A1 (en) | 2002-05-06 | 2003-11-20 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
EP1545578A4 (en) | 2002-08-28 | 2010-07-07 | Immunex Corp | Compositions and methods for treating cardiovascular disease |
CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
CN1688293A (en) * | 2002-09-16 | 2005-10-26 | 韦思公司 | Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same |
CN101914559B (en) | 2002-10-04 | 2012-04-04 | 弗门尼舍有限公司 | Sesquiterpene synthases and methods of use |
AU2003273640A1 (en) * | 2002-10-10 | 2004-05-04 | K.U. Leuven Research And Development | Autism gene |
US20040175359A1 (en) * | 2002-11-12 | 2004-09-09 | Desjarlais John Rudolph | Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity |
AU2003299872A1 (en) | 2002-12-20 | 2004-07-22 | Board Of Regents, The University Of Texas System | Vmp-like sequences of pathogenic borrelia species and strains |
CA2533512C (en) | 2003-07-25 | 2013-06-11 | Amgen Inc. | Antagonists and agonists of ldcam and methods of use |
WO2005016380A1 (en) * | 2003-07-30 | 2005-02-24 | Chiron Corporation | Methods of therapy for chronic lymphocytic leukemia |
US20070274988A1 (en) * | 2003-10-10 | 2007-11-29 | Five Prime Therapeautics, Inc. | Kiaa0779, Splice Variants Thereof, and Methods of Their Use |
ATE447412T1 (en) | 2003-11-04 | 2009-11-15 | Novartis Vaccines & Diagnostic | ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES AND METHODS OF USE |
AU2004297988A1 (en) * | 2003-12-04 | 2005-06-23 | Laboratoires Serono Sa | Methods for identifying modulators of active KIT tyrosine kinase receptor |
JP2007527242A (en) * | 2004-03-05 | 2007-09-27 | カイロン コーポレーション | In vitro test system for predicting patient tolerance of therapeutic agents |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US20080076729A1 (en) * | 2005-05-19 | 2008-03-27 | Schering Aktiengesellachaft | Interferon-beta gene therapy using an improved, regulated expression system |
US20070179113A1 (en) * | 2005-05-19 | 2007-08-02 | Schering Aktiengesellachaft | GM-CSF gene therapy for Crohn's disease using an improved regulated expression system |
EP1891224A1 (en) * | 2005-05-19 | 2008-02-27 | Bayer Schering Pharma Aktiengesellschaft | Interferon-beta gene therapy using an improved, regulated expression system |
WO2006122971A2 (en) * | 2005-05-19 | 2006-11-23 | Bayer Schering Pharma Aktiengesellschaft | Treatment of disease using an improved regulated expression system |
JP5164167B2 (en) | 2005-08-30 | 2013-03-13 | ユニバーシティー オブ マイアミ | Agonists, antagonists and immunotoxins of immunoregulatory tumor necrosis factor receptor 25 (TNFR25) |
US8026354B2 (en) | 2005-11-23 | 2011-09-27 | Institut Pasteur | Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use |
WO2007064844A2 (en) | 2005-12-01 | 2007-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Anti-viral griffithsin compounds, compositions, and methods of use |
WO2007075906A2 (en) | 2005-12-23 | 2007-07-05 | Kelly James D | Improved thyroid-stimulating hormone receptor polypeptide agonist glycoforms to treat metabolic syndrome |
US7868228B2 (en) | 2006-01-31 | 2011-01-11 | Monsanto Technology Llc | Phosphopantetheinyl transferases from bacteria |
WO2007110231A2 (en) * | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
US8129334B2 (en) | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
EP1872790A1 (en) | 2006-06-26 | 2008-01-02 | DeveloGen Aktiengesellschaft | New formulation for increasing bioavailability of neurturin |
US20080069796A1 (en) * | 2006-07-31 | 2008-03-20 | Kim Jong-Mook | Low Dose Treatment with an Interleukin-11 Analog |
CL2007002567A1 (en) | 2006-09-08 | 2008-02-01 | Amgen Inc | ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN. |
WO2008125222A2 (en) * | 2007-04-11 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | New modulation molecules for an improved regulated expression system |
WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
EP2207890A4 (en) * | 2007-10-05 | 2010-12-15 | Barofold Inc | High pressure treatment of aggregated interferons |
KR101041986B1 (en) | 2008-03-06 | 2011-06-16 | (주)한국비엠아이 | Production method of host microorganism having high yield productivity of recombinant human active protein |
WO2009152610A1 (en) * | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
PT2337791E (en) | 2008-10-14 | 2013-11-29 | Monsanto Technology Llc | Utilization of fatty acid desaturases from hemiselmis spp |
JP2012507565A (en) | 2008-10-30 | 2012-03-29 | グオ・ペイシュエン | Viral DNA packaging motor protein connector biosensor embedded in membrane for DNA sequencing and other applications |
WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
CA2757178C (en) | 2009-04-03 | 2020-05-19 | Medical Research Council | Mutants of activation-induced cytidine deaminase (aid) and methods of use |
CA2806840C (en) | 2009-08-03 | 2019-08-27 | Eckhard R. Podack | Method for in vivo expansion of t regulatory cells |
WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
US20110117092A1 (en) * | 2009-10-20 | 2011-05-19 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting g-csfr |
EP2494356B1 (en) * | 2009-10-26 | 2017-03-15 | Genentech, Inc. | Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis |
CN102933084B (en) | 2009-10-28 | 2014-12-31 | 柑橘病虫害预防基金会 | Repellent compositions and genetic approaches for controlling huanglongbing |
LT2637694T (en) * | 2010-11-12 | 2021-05-25 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
EP2654786B1 (en) | 2010-12-20 | 2019-02-20 | GenVec, Inc. | Adenoviral vector-based dengue fever vaccine |
ES2778053T3 (en) | 2011-01-18 | 2020-08-07 | Bioniz Llc | Compositions to modulate gamma-c cytokine activity |
EP2670426B1 (en) | 2011-01-31 | 2017-05-10 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
JP2014510265A (en) | 2011-02-02 | 2014-04-24 | アムジェン インコーポレイテッド | Methods and compositions for inhibition of IGF-IR |
PE20140303A1 (en) | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | MUTANT INTERLEUQUIN-2 POLYPEPTIDES |
RU2644346C2 (en) | 2011-06-01 | 2018-02-08 | Интрексон Актобиотикс Н.В. | System of polycistronic expression for bacteria |
WO2013009971A1 (en) | 2011-07-12 | 2013-01-17 | E. I. Du Pont De Nemours And Company | Detection and screening method and materials useful in performance thereof |
AU2013222414B2 (en) | 2012-02-21 | 2018-02-15 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
ES2779698T3 (en) | 2012-03-19 | 2020-08-18 | Brigham & Womens Hospital Inc | Growth differentiation factor 11 (GDF) for the treatment of age-related cardiovascular conditions |
US9441039B2 (en) | 2012-05-07 | 2016-09-13 | Amgen Inc. | Anti-erythropoietin antibodies |
SG11201407784UA (en) | 2012-05-30 | 2014-12-30 | Harvard College | Engineered botulinum neurotoxin |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
EP2877572B1 (en) | 2012-07-24 | 2018-11-28 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
US9962436B2 (en) | 2012-07-26 | 2018-05-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
US9309318B2 (en) | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
AU2013344701A1 (en) * | 2012-11-15 | 2015-05-28 | Board Of Supervisors Of Louisiana State Universtity And Agricultural And Mechanical College | Follicle-stimulating hormone (FSH)/lytic domain fusion constructs and methods of making and using same |
KR20150136047A (en) | 2013-01-09 | 2015-12-04 | 유니버시티 오브 마이애미 | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
MX2015009901A (en) | 2013-02-01 | 2016-04-06 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject. |
US9951340B2 (en) | 2013-03-07 | 2018-04-24 | The General Hospital Corporation | Compositions and methods for bacterial delivery of polypeptides |
AU2014236867A1 (en) | 2013-03-15 | 2015-09-24 | Amgen Inc. | Methods and compositions relating to anti-CCR7 antigen binding proteins |
CN112870368A (en) | 2013-03-27 | 2021-06-01 | 西达-赛奈医疗中心 | Reduction and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways |
JP2016518357A (en) | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Methods and compositions for rejuvenating skeletal muscle stem cells |
AU2014268603B2 (en) | 2013-05-21 | 2018-03-22 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
EP3881859B1 (en) | 2013-06-11 | 2024-03-06 | President and Fellows of Harvard College | Compositions for increasing neurogenesis and angiogenesis |
WO2015003114A1 (en) | 2013-07-05 | 2015-01-08 | University Of Washington Through Its Center For Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
AU2014312249A1 (en) | 2013-08-28 | 2016-03-24 | Cytonics Corporation | Systems, compositions, and methods for transplantation and treating conditions |
US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
EP3082834B1 (en) | 2013-12-11 | 2020-03-11 | The General Hospital Corporation DBA Massachusetts | Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors |
WO2015106086A1 (en) | 2014-01-09 | 2015-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-viral cnidarins |
US9487763B2 (en) | 2014-01-22 | 2016-11-08 | Regents Of The University Of Michigan | Nonribosomal peptide synthetases |
US9994885B2 (en) | 2014-01-22 | 2018-06-12 | Regents Of The University Of Michigan | Nonribosomal peptide synthetases |
MX370283B (en) | 2014-02-06 | 2019-12-09 | Hoffmann La Roche | Interleukin-2 fusion proteins and uses thereof. |
US10400028B2 (en) | 2014-11-20 | 2019-09-03 | Cytonics Corporation | Therapeutic variant alpha-2-macroglobulin compositions |
US10889631B2 (en) | 2014-11-20 | 2021-01-12 | Cytonics Corporation | Therapeutic variant alpha-2-macroglobulin compositions |
CN111018987B (en) | 2014-12-05 | 2023-11-21 | 鸿运华宁(杭州)生物医药有限公司 | Antibody capable of specifically binding to human endothelin receptor and application thereof |
EP3274364B1 (en) | 2015-03-26 | 2021-08-04 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
WO2016168601A1 (en) | 2015-04-17 | 2016-10-20 | Khalid Shah | Agents, systems and methods for treating cancer |
JP2018522547A (en) | 2015-06-15 | 2018-08-16 | モナッシュ ユニバーシティ | IL-37 variant |
CA2994729A1 (en) | 2015-08-27 | 2017-03-02 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
JP2018535655A (en) | 2015-09-29 | 2018-12-06 | アムジエン・インコーポレーテツド | ASGR inhibitor |
CN108350032A (en) | 2015-10-09 | 2018-07-31 | 比奥尼斯有限责任公司 | Adjust γ C- cytokine activities |
WO2017070744A1 (en) | 2015-10-30 | 2017-05-04 | Monash University | Methods and compositions for improving glucose metabolism |
JP7325186B2 (en) | 2015-12-09 | 2023-08-14 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Type II anti-CD20 antibody for reducing the formation of anti-drug antibodies |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
CA3011331A1 (en) | 2016-01-14 | 2017-07-20 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
WO2017161342A1 (en) | 2016-03-17 | 2017-09-21 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through rnaset2 |
TWI826351B (en) | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧(杭州)生物醫藥有限公司 | R antibodies, their pharmaceutical compositions and uses |
US11117935B2 (en) | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
ES2963830T3 (en) | 2016-10-20 | 2024-04-02 | Harvard College | In vitro and cell-based assays to measure botulinum neurotoxin activity |
EP3532489A4 (en) | 2016-10-26 | 2020-07-08 | Cedars-Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
EP3585819A4 (en) | 2017-02-27 | 2020-10-14 | Caerus Therapeutics, Inc. | Antibody constructs and methods of treating cancer |
LT3606946T (en) | 2017-04-03 | 2022-10-25 | F. Hoffmann-La Roche Ag | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
WO2018184965A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
AU2018250875A1 (en) | 2017-04-13 | 2019-10-03 | F. Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer |
CN112105632A (en) * | 2018-01-24 | 2020-12-18 | 北京智康博药肿瘤医学研究有限公司 | Cytokine fusion proteins |
WO2019147982A1 (en) | 2018-01-26 | 2019-08-01 | Celldex Therapeutics, Inc. | Methods of treating cancer with dendritic cell mobilizing agents |
CN117126279A (en) | 2018-03-20 | 2023-11-28 | 鸿运华宁(杭州)生物医药有限公司 | GIPR antibody and fusion protein of GIPR antibody and GLP-1, and pharmaceutical composition and application thereof |
EP3768299A1 (en) | 2018-03-22 | 2021-01-27 | The Children's Medical Center Corporation | Methods and compositions relating to lung repair |
CN110357959B (en) | 2018-04-10 | 2023-02-28 | 鸿运华宁(杭州)生物医药有限公司 | GCGR antibody, fusion protein of GCGR antibody and GLP-1, and pharmaceutical composition and application of GCGR antibody and fusion protein |
CN112585165A (en) | 2018-04-25 | 2021-03-30 | 普罗米修斯生物科学公司 | Optimized anti-TL 1A antibodies |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
EP3807305A4 (en) | 2018-06-13 | 2022-04-20 | Akron Biotechnology, LLC | Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions |
CN110655577A (en) | 2018-06-13 | 2020-01-07 | 鸿运华宁(杭州)生物医药有限公司 | APJ antibody and fusion protein thereof with Elabela, and pharmaceutical composition and application thereof |
JP2022501009A (en) | 2018-09-21 | 2022-01-06 | イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド | New interleukin 2 and its use |
US20210221863A1 (en) | 2018-09-21 | 2021-07-22 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
EP3930757A1 (en) | 2019-03-01 | 2022-01-05 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
US20220257767A1 (en) | 2019-04-03 | 2022-08-18 | President And Fellows Of Harvard College | Ionic liquids for drug delivery |
EP3994169A1 (en) | 2019-07-02 | 2022-05-11 | F. Hoffmann-La Roche AG | Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody |
CN112239507A (en) | 2019-07-17 | 2021-01-19 | 鸿运华宁(杭州)生物医药有限公司 | Fusion protein of ETA antibody and TGF-beta Trap, and pharmaceutical composition and application thereof |
CN112521501A (en) | 2019-09-18 | 2021-03-19 | 鸿运华宁(杭州)生物医药有限公司 | GIPR antibody and fusion protein thereof with GLP-1, and pharmaceutical composition and application thereof |
AU2020356592A1 (en) | 2019-09-27 | 2022-04-07 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Treatment of celiac disease |
CN114901311A (en) | 2019-10-24 | 2022-08-12 | 普罗米修斯生物科学公司 | Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof |
JP2023503899A (en) | 2019-11-22 | 2023-02-01 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Ionic liquids for drug delivery |
CN114846024A (en) | 2019-12-20 | 2022-08-02 | 豪夫迈·罗氏有限公司 | IL-37 fusion proteins and uses thereof |
CN115023444A (en) | 2019-12-20 | 2022-09-06 | 再生元制药公司 | Novel IL2 agonists and methods of use thereof |
MX2022008648A (en) | 2020-01-23 | 2022-12-15 | The Children´S Medical Center Corp | Stroma-free t cell differentiation from human pluripotent stem cells. |
GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
GB202003611D0 (en) | 2020-03-12 | 2020-04-29 | Univ Oxford Innovation Ltd | Stabilised viral fusion proteins |
CA3175717A1 (en) | 2020-03-19 | 2021-09-23 | Innovent Biologics (Suzhou) Co., Ltd. | Interleukin-2 mutant and use thereof |
JP2023518443A (en) | 2020-03-19 | 2023-05-01 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | Interleukin-2 mutants and uses thereof |
GB202006803D0 (en) | 2020-05-07 | 2020-06-24 | Imperial College Innovations Ltd | Method for identifying RNA binding protein binding sites on RNA |
CN115551540A (en) | 2020-05-11 | 2022-12-30 | 豪夫迈·罗氏有限公司 | Combination therapy using modified PBMCs and immunoconjugates |
TW202219065A (en) | 2020-06-19 | 2022-05-16 | 瑞士商赫孚孟拉羅股份公司 | Immune activating Fc domain binding molecules |
GB2596820A (en) | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
CA3184940A1 (en) | 2020-07-07 | 2022-01-13 | Jennifer Donglan WU | Mic antibodies and binding agents and methods of using the same |
CA3184852A1 (en) | 2020-07-10 | 2022-01-13 | Lida Katsimpardi | Use of gdf11 to diagnose and treat anxiety and depression |
KR20230040359A (en) | 2020-07-17 | 2023-03-22 | 트르스티스 오브 보스톤 유니버시티 | Virus detection system and its use |
TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
CN116635403A (en) | 2020-12-04 | 2023-08-22 | 豪夫迈·罗氏有限公司 | PH-dependent mutant interleukin-2 polypeptides |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
WO2022161355A1 (en) | 2021-01-26 | 2022-08-04 | Cytocares (Shanghai) Inc. | Chimeric antigen receptor (car) constructs and nk cells expressing car constructs |
EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
CN115141276A (en) | 2021-03-31 | 2022-10-04 | 鸿运华宁(杭州)生物医药有限公司 | Antibody capable of being specifically combined with human endothelin receptor and application thereof in treatment of diabetic nephropathy and chronic nephropathy |
TW202304524A (en) | 2021-04-10 | 2023-02-01 | 美商普方生物製藥美國公司 | Folr1 binding agents, conjugates thereof and methods of using the same |
EP4326768A1 (en) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
TW202317623A (en) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | Il2-based therapeutics and methods of use thereof |
CA3223081A1 (en) | 2021-07-15 | 2023-01-19 | Samir Mitragotri | Compositions and methods relating to cells with adhered particles |
CA3233824A1 (en) | 2021-10-08 | 2023-04-13 | Samir Mitragotri | Ionic liquids for drug delivery |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
US20230382969A1 (en) | 2022-05-27 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
US20230391844A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0028033A2 (en) * | 1979-10-30 | 1981-05-06 | Juridical Foundation Japanese Foundation for Cancer Research | Double-stranded DNA which codes for a polypeptide with human fibroblast interferon activity, cloned DNA, recombinant plasmid containing the DNA and microorganism containing the recombinant plasmid |
EP0041313A2 (en) * | 1980-04-03 | 1981-12-09 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon |
EP0042246A2 (en) * | 1980-06-12 | 1981-12-23 | The Cancer Institute Of Japanese Foundation For Cancer Research | Plasmid |
US4401756A (en) * | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
US4414150A (en) * | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4448879A (en) * | 1981-03-26 | 1984-05-15 | Hooper Trading Company | High yield process for in vitro production of serum-free and mitogen-free interleukin-2 |
US4490289A (en) * | 1982-09-16 | 1984-12-25 | Hoffmann-La Roche Inc. | Homogeneous human interleukin 2 |
US4564593A (en) * | 1981-12-28 | 1986-01-14 | Takeda Chemical Industries, Ltd. | Messenger RNA, production and use thereof |
US4738927A (en) * | 1982-03-31 | 1988-04-19 | Ajinomoto Co. Inc. | Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell |
US4778879A (en) * | 1982-04-20 | 1988-10-18 | Sloan-Kettering Institute For Cancer Research | Highly purified human interleukin 2 and method |
-
1983
- 1983-12-20 US US06/564,224 patent/US4518584A/en not_active Ceased
-
1989
- 1989-07-26 US US07/386,207 patent/USRE33653E/en not_active Expired - Lifetime
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0028033A2 (en) * | 1979-10-30 | 1981-05-06 | Juridical Foundation Japanese Foundation for Cancer Research | Double-stranded DNA which codes for a polypeptide with human fibroblast interferon activity, cloned DNA, recombinant plasmid containing the DNA and microorganism containing the recombinant plasmid |
EP0041313A2 (en) * | 1980-04-03 | 1981-12-09 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon |
EP0042246A2 (en) * | 1980-06-12 | 1981-12-23 | The Cancer Institute Of Japanese Foundation For Cancer Research | Plasmid |
US4414150A (en) * | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4448879A (en) * | 1981-03-26 | 1984-05-15 | Hooper Trading Company | High yield process for in vitro production of serum-free and mitogen-free interleukin-2 |
US4401756A (en) * | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
US4564593A (en) * | 1981-12-28 | 1986-01-14 | Takeda Chemical Industries, Ltd. | Messenger RNA, production and use thereof |
US4738927A (en) * | 1982-03-31 | 1988-04-19 | Ajinomoto Co. Inc. | Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell |
US4778879A (en) * | 1982-04-20 | 1988-10-18 | Sloan-Kettering Institute For Cancer Research | Highly purified human interleukin 2 and method |
US4490289A (en) * | 1982-09-16 | 1984-12-25 | Hoffmann-La Roche Inc. | Homogeneous human interleukin 2 |
Non-Patent Citations (30)
Title |
---|
Allen et al., Nature, vol. 287, pp. 408 410, (1980). * |
Allen et al., Nature, vol. 287, pp. 408-410, (1980). |
Altman et al., Proc. Natl. Acad. Sci., vol. 81, pp. 2176 2180, (1984). * |
Altman et al., Proc. Natl. Acad. Sci., vol. 81, pp. 2176-2180, (1984). |
Glossary of Genetics and Cytogenetics, 4th Ed., p. 381, Springer Verlag, (1976). * |
Glossary of Genetics and Cytogenetics, 4th Ed., p. 381, Springer-Verlag, (1976). |
Goeddel et al., Nucleic Acids Research, vol. 8, No. 18, pp. 4057 4074, (1980). * |
Goeddel et al., Nucleic Acids Research, vol. 8, No. 18, pp. 4057-4074, (1980). |
Knight et al., J. Interferon Res., vol. 2, No. 3, pp. 421 429, (1982). * |
Knight et al., J. Interferon Res., vol. 2, No. 3, pp. 421-429, (1982). |
Lathe et al., Genetic Engineering, Academic Press, (1983), pp. 31 50. * |
Lathe et al., Genetic Engineering, Academic Press, (1983), pp. 31-50. |
Levy et al., PNAS, vol. 78, No. 10, pp. 6186 6190, (1981). * |
Levy et al., PNAS, vol. 78, No. 10, pp. 6186-6190, (1981). |
Liang et al., J. Biol. Chem., vol. 261, No. 1, pp. 334 337, (1986). * |
Liang et al., J. Biol. Chem., vol. 261, No. 1, pp. 334-337, (1986). |
Shepard et al., Nature, vol. 294, pp. 563 565, (1981). * |
Shepard et al., Nature, vol. 294, pp. 563-565, (1981). |
Shiroishi et al., Proc. Natl. Acad. Sci., vol. 81, pp. 7544 7548, (1984). * |
Shiroishi et al., Proc. Natl. Acad. Sci., vol. 81, pp. 7544-7548, (1984). |
Smith et al., Genetic Engineering, Principles and Methods, Plenum Press, (1981), 3:1 32. * |
Smith et al., Genetic Engineering, Principles and Methods, Plenum Press, (1981), 3:1-32. |
Stern et al., Proc. Natl. Acad. Sci., vol. 81, pp. 871 875, (1984). * |
Stern et al., Proc. Natl. Acad. Sci., vol. 81, pp. 871-875, (1984). |
Taniguchi et al., Gene, vol. 10, pp. 11 15, (1980). * |
Taniguchi et al., Gene, vol. 10, pp. 11-15, (1980). |
Taniguchi et al., Nature, vol. 285, pp. 547 549, (1980). * |
Taniguchi et al., Nature, vol. 285, pp. 547-549, (1980). |
Taniguchi et al., PNAS, vol. 77, No. 9, pp. 5230 5233, (1980). * |
Taniguchi et al., PNAS, vol. 77, No. 9, pp. 5230-5233, (1980). |
Cited By (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030036170A1 (en) * | 1992-01-31 | 2003-02-20 | Aventis Behring L.L.C. | Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
US7081354B2 (en) | 1992-01-31 | 2006-07-25 | Aventis Behring L.L.C. | Interleukin and albumin fusion protein |
US5972596A (en) | 1992-03-27 | 1999-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleic acid constructs containing HIV genes with mutated inhibitory/instability regions and methods of using same |
US6291664B1 (en) | 1992-03-27 | 2001-09-18 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions of mRNA |
US5965726A (en) | 1992-03-27 | 1999-10-12 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/ instability regions of mRNA |
US6794498B2 (en) | 1992-03-27 | 2004-09-21 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions of mRNA |
US6414132B1 (en) | 1992-03-27 | 2002-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions of mRNA |
US5674834A (en) * | 1993-02-02 | 1997-10-07 | Xoma Corporation | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
US6828418B2 (en) | 1993-02-02 | 2004-12-07 | Xoma Corporation | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
US20060009383A1 (en) * | 1993-02-02 | 2006-01-12 | Georgia Theofan | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
US6433140B1 (en) | 1993-02-02 | 2002-08-13 | Xoma Corporation | Stable bactericidal permeability-increasing protein products and pharmaceutical compositions containing the same |
US5827816A (en) * | 1993-02-02 | 1998-10-27 | Xoma Corporation | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
EP2042509A1 (en) | 1995-07-16 | 2009-04-01 | Yeda Research And Development Company, Ltd. | Modulators of the function of FAS receptors and other proteins |
US6008319A (en) | 1996-12-23 | 1999-12-28 | University Of Southern California | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof |
US6403096B1 (en) | 1996-12-23 | 2002-06-11 | University Of Southern California | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof |
US6737064B2 (en) | 1996-12-23 | 2004-05-18 | The University Of Southern California | Method for the diagnosis of neoplastic tissue comprising administering a vasopermeability enhancing peptide of human interleukin-2 |
US20080004217A1 (en) * | 1998-12-30 | 2008-01-03 | Applied Research Systems Ars | Treatment of hiv-associated dysmorphia/dysmetabolic syndrome (hadds) with or without lipodystrophy |
US7144577B2 (en) | 1998-12-30 | 2006-12-05 | Applied Research Systems Ars | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
US6696063B1 (en) | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
US6689879B2 (en) | 1998-12-31 | 2004-02-10 | Chiron Corporation | Modified HIV Env polypeptides |
US20110212164A1 (en) * | 1998-12-31 | 2011-09-01 | Novartis Vaccines & Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US20100316698A1 (en) * | 1998-12-31 | 2010-12-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US8541230B2 (en) | 1998-12-31 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US20030223964A1 (en) * | 1998-12-31 | 2003-12-04 | Susan Barnett | Expression of HIV polypeptides and production of virus-like particles |
US8263394B2 (en) | 1998-12-31 | 2012-09-11 | Novartis Vaccines & Diagnostics Inc. | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides, and uses thereof |
US20060057115A1 (en) * | 1998-12-31 | 2006-03-16 | Zur Megede Jan | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US7662916B2 (en) | 1998-12-31 | 2010-02-16 | Novartis Vaccines & Diagnostics, Inc | Modified HIV Env polypeptides |
US7718401B2 (en) | 1998-12-31 | 2010-05-18 | Novartis Vaccines And Diagnostics, Inc. | Expression of HIV polypeptides and production of virus-like particles |
US20090047339A1 (en) * | 1998-12-31 | 2009-02-19 | Barnett Susan W | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US20090004733A1 (en) * | 1998-12-31 | 2009-01-01 | Novartis Vaccines & Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides, and uses thereof |
US8168418B2 (en) | 1998-12-31 | 2012-05-01 | Susan W Barnett | Expression of HIV polypeptides and production of virus-like particles |
US7943375B2 (en) | 1998-12-31 | 2011-05-17 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US20080261271A1 (en) * | 1998-12-31 | 2008-10-23 | Novartis Vaccines & Diagnostics, Inc. | Expression of hiv polypeptides and production of virus-like particles |
US6602705B1 (en) | 1998-12-31 | 2003-08-05 | Chiron Corporation | Expression of HIV polypeptides and production of virus-like particles |
US20100092502A1 (en) * | 1998-12-31 | 2010-04-15 | Novartis Vaccines And Diagnostics, Inc. | Modified hiv env polypeptides |
US7348177B2 (en) | 1998-12-31 | 2008-03-25 | Novartis Vaccines And Diagnostics, Inc. | Expression of HIV polypeptides and production of virus-like particles |
US20030223961A1 (en) * | 2000-07-05 | 2003-12-04 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US6689783B2 (en) | 2001-03-29 | 2004-02-10 | Schering Corporation | Aryl oxime-piperazines useful as CCR5 antagonists |
US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US20080089908A1 (en) * | 2001-07-05 | 2008-04-17 | Megede Jan Z | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US20030198621A1 (en) * | 2001-07-05 | 2003-10-23 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
US8133494B2 (en) | 2001-07-05 | 2012-03-13 | Novartis Vaccine & Diagnostics Inc | Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2 |
US9598469B2 (en) | 2001-07-05 | 2017-03-21 | Novartis Vaccines And Diagnostics, Inc. | HIV-1 south african subtype C env proteins |
US20060292116A1 (en) * | 2001-08-13 | 2006-12-28 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
US8124066B2 (en) | 2001-08-13 | 2012-02-28 | University Of Southern California | Methods of using interleukin-2 mutants with reduced toxicity |
US7514073B2 (en) | 2001-08-13 | 2009-04-07 | University Of Southern California | Therapeutic use of interleukin-2 mutants |
US20110091413A1 (en) * | 2001-08-13 | 2011-04-21 | University Of Southern California | Therapeutic use of interleukin-2 mutants |
US7371371B2 (en) | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
US7803361B2 (en) | 2001-08-13 | 2010-09-28 | University Of Southern California | Therapeutic use of interleukin-2 mutants |
US20030124678A1 (en) * | 2001-08-13 | 2003-07-03 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
US20090274653A1 (en) * | 2001-08-13 | 2009-11-05 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
US20050214256A1 (en) * | 2001-08-31 | 2005-09-29 | Chiron Corporation | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US7282364B2 (en) | 2001-08-31 | 2007-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US20080095833A1 (en) * | 2001-08-31 | 2008-04-24 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides, and uses thereof |
US20070020622A1 (en) * | 2001-09-14 | 2007-01-25 | Invitrogen Corporation | DNA Polymerases and mutants thereof |
EP2322229A2 (en) | 2001-10-10 | 2011-05-18 | Novo Nordisk A/S | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
EP2279753A2 (en) | 2001-10-10 | 2011-02-02 | Novo Nordisk A/S | Remodeling and glycoconjugation of peptides |
EP2042196A2 (en) | 2001-10-10 | 2009-04-01 | Neose Technologies, Inc. | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
EP2305314A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Remodelling and glycoconjugation of antibodies |
EP2080525A1 (en) | 2001-10-10 | 2009-07-22 | BioGeneriX AG | Remodeling and Glycoconjugation of Peptides |
EP2305312A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
EP2305313A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Remodelling and glycoconjugation of interferon-alpha (IFNa) |
EP2305311A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Glycoconjugation of peptides |
EP2298354A2 (en) | 2001-10-10 | 2011-03-23 | BioGeneriX AG | Remodelling and glycoconjugation of interferon-beta |
EP2279754A2 (en) | 2001-10-10 | 2011-02-02 | BioGeneriX AG | Remodelling and glycoconjugation of human growth hormone (hGH) |
EP2279755A2 (en) | 2001-10-10 | 2011-02-02 | BioGeneriX AG | Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF) |
US20050164185A1 (en) * | 2001-12-31 | 2005-07-28 | Gideon Schreiber | Ifnar2 mutants, their production and use |
EP2174955A1 (en) | 2001-12-31 | 2010-04-14 | Yeda Research And Development Co. Ltd. | Ifnar2 muteins, their production and use |
US7749735B2 (en) | 2001-12-31 | 2010-07-06 | Yeda Research And Development Co., Ltd. | IFNAR2 mutants, their production and use |
US20060029572A1 (en) * | 2002-06-03 | 2006-02-09 | Applied Research Systems Ars Holding N.V. | Treatment of hepatitis c in the asian population with subcutaneous interferonbeta |
US7344709B2 (en) | 2002-06-03 | 2008-03-18 | Laboratories Serono Sa | Treatment of hepatitis C in the Asian population with subcutaneous interferon-beta |
WO2004085406A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
US9463241B2 (en) | 2003-04-09 | 2016-10-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for stabilising an immunoglobulin G composition in liquid form |
EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US8388954B2 (en) | 2003-04-09 | 2013-03-05 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Stabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form |
EP2338333A2 (en) | 2003-04-09 | 2011-06-29 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
US20080025957A1 (en) * | 2003-11-13 | 2008-01-31 | Yeda Research And Development Co. Ltd. P. O. Box 95 | Stem Cells Suitable for Transplantation, their Preparation and Pharmaceutical Compositions Comprising Them |
US8367057B2 (en) | 2003-11-13 | 2013-02-05 | Yeda Research And Development Co. Ltd. | Stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them |
EP2045265A1 (en) | 2005-09-22 | 2009-04-08 | Biocompatibles Uk Ltd. | GLP-1 fusion peptides, their production and use |
EP2174952A2 (en) | 2005-09-22 | 2010-04-14 | Biocompatibles Uk Ltd. | glp-1 (glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance |
EP2261245A1 (en) | 2005-09-22 | 2010-12-15 | Biocompatibles Uk Ltd. | GLP-1 (glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance |
WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
WO2008019968A1 (en) | 2006-08-16 | 2008-02-21 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
WO2008071587A2 (en) | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors |
WO2008145562A1 (en) | 2007-05-30 | 2008-12-04 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
WO2009080534A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
WO2009098700A1 (en) | 2008-02-10 | 2009-08-13 | Yeda Research And Development Co. Ltd | Siva 3, its preparation and use |
US9732134B2 (en) | 2009-01-21 | 2017-08-15 | Amgen Inc. | Method of treating graft versus host disease using IL-2 muteins |
US11560415B2 (en) | 2009-01-21 | 2023-01-24 | Amgen Inc. | Method of promoting regulatory T-cell proliferation |
US10851144B2 (en) | 2015-04-10 | 2020-12-01 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10961310B2 (en) | 2017-03-15 | 2021-03-30 | Pandion Operations, Inc. | Targeted immunotolerance |
US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
US11466068B2 (en) | 2017-05-24 | 2022-10-11 | Pandion Operations, Inc. | Targeted immunotolerance |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US11091527B2 (en) | 2017-12-06 | 2021-08-17 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US11091526B2 (en) | 2017-12-06 | 2021-08-17 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US11779632B2 (en) | 2017-12-06 | 2023-10-10 | Pandion Operation, Inc. | IL-2 muteins and uses thereof |
US11945852B2 (en) | 2017-12-06 | 2024-04-02 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US11965008B2 (en) | 2017-12-06 | 2024-04-23 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
US11491205B2 (en) | 2020-01-14 | 2022-11-08 | Synthekine, Inc. | Biased IL2 muteins methods and compositions |
Also Published As
Publication number | Publication date |
---|---|
US4518584A (en) | 1985-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE33653E (en) | Human recombinant interleukin-2 muteins | |
US4853332A (en) | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins | |
US4588585A (en) | Human recombinant cysteine depleted interferon-β muteins | |
EP0192811B1 (en) | Cysteine-depleted muteins of biologically active proteins, their preparation, formulations containing them, and structural genes, vectors and organisms, and their production, suitable for use in the preparation of said muteins | |
US4959314A (en) | Cysteine-depleted muteins of biologically active proteins | |
US4737462A (en) | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β | |
EP0077670B1 (en) | Human immune interferon | |
Goeddel et al. | The structure of eight distinct cloned human leukocyte interferon cDNAs | |
US6610830B1 (en) | Microbial production of mature human leukocyte interferons | |
EP0043980B1 (en) | Mature human leukocyte interferon a, process for its microbial preparation, intermediates therefor and compositions containing it. | |
US5096705A (en) | Human immune interferon | |
US5004689A (en) | DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields | |
US5582824A (en) | Recombinant DES-CYS-TYR-CYS human immune interferon | |
US4801685A (en) | Microbial production of mature human leukocyte interferon K and L | |
JPH057996B2 (en) | ||
EP0299782A2 (en) | Expression vectors for the production of human Granulocyte-Macrophage Colony Stimulation Factor in a mammalian cell host(18.05.92) | |
EP0099389A1 (en) | Interferon-alpha 54 | |
BG60506B2 (en) | Human recombinant interleukin-2-mutien | |
BG60510B2 (en) | Structural genes, plasmides and transformed cells for the production of cystein-poor muteins of biologically active proteins | |
FI87233B (en) | Gene which codes for a mutein | |
AU2131688A (en) | Human granulocyte-macrophage colony stimulating factor and muteins thereof | |
NO306951B1 (en) | DNA sequence encoding a modified human IFM (beta) and method for its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: CETUS ONCOLOGY CORPORATION Free format text: CHANGE OF NAME;ASSIGNOR:CETUS CORPORATION, A CORP. OF DE;REEL/FRAME:006163/0225 Effective date: 19920304 |
|
PTEF | Application for a patent term extension |
Free format text: PRODUCT NAME: PROLEUKIN (ALDESLEUKIN); REQUESTED FOR 1445 DAYS Filing date: 19920616 Expiry date: 20020521 |
|
AS | Assignment |
Owner name: CETUS ONCOLOGY CORPORATION Free format text: CHANGE OF NAME;ASSIGNOR:CETUS CORPORATION;REEL/FRAME:006268/0881 Effective date: 19920304 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
PTEG | Grant of a patent term extension |
Free format text: PRODUCT NAME: PROLEUKIN (ALDESLEUKIN) Filing date: 19920616 Expiry date: 20020521 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: CHIRON CORPORATION, CALIFORNIA Free format text: MERGER;ASSIGNOR:CETUS ONCOLOGYCORPORATION (FORMERLY CETUS CORPORATION);REEL/FRAME:008209/0087 Effective date: 19960325 |